Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Cancer Metastatic, Gastrointestinal Adenocarcinoma, Gastrointestinal Cancers, Colorectal (Colon or Rectal) Cancer, Pancreatic Cancer, CDH17-positive Advanced Solid Tumors, Advanced Gastric Cancer

In brief

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.

Key facts

Study ID

NCT07529808

Run by

BigHat Biosciences, Inc.

People needed

164

Starts

2026-07-01

Expected to finish

2028-12-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
• Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.
• Participants in Phase 1 Backfill Cohorts \& Phase 2 must be CDH17-positive by central testing.
• Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
• At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
• Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.
• Adequate organ and marrow function as defined in the protocol

You may not qualify if…

• Prior cancer treatment as follows, relative to the first planned dose of trial intervention:
• Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
• Monoclonal antibody-based therapy (including ADCs) within 4 weeks
• Immune checkpoint inhibitors within 4 weeks
• Wide-field radiation therapy (>30% marrow-bearing bones) within 4 weeks or < 2 weeks of focal palliative radiation to nontarget lesions
• Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)
• Known hypersensitivity or allergic reaction to BHB810 or it's excipients
• Left ventricular ejection fraction <50% or history of congestive heart failure Class III/IV
• QTc interval > 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc
• Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant
• Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.
• Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention
• Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.

Where it is running

• NEXT Virginia — Fairfax, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.